, Volume 54, Issue 12, pp 1026-1028

Anesthesiologists and the pharmaceutical industry: awareness is paramount

Disclosure statement: François Hélie held manager positions with Genizon BioSciences, Montreal (Genetics, Clinical Research; 2002 to 2005) and Bayer HealthCare Pharmaceuticals, Toronto (Medical & Scientific Affairs; 2005 to 2007).
Jean-François Hardy has, since 1984, received funding from the following pharmaceutical companies: Janssen Pharmaceuticals (research funding), Sterling Drugs (research funding), Kabi Pharmacia (research funding), Ibex Technologies (research funding), Hemosol Inc. (lecturing and research funding), Ortho Biotech (lecturing and research funding), Bayer Inc (lecturing and research funding), Novo Nordisk (lecturing). Jean-François Hardy is Chairman of the Data Monitoring Committee of the ongoing study on rHuFVIIa in cardiac surgery sponsored by Novo Nordisk and, as such, cannot engage in any marketing activities (e.g., lectures, symposia, etc.) of that company.
On behalf of the panel members of the Canadian Consensus Conference on the role of recombinant factor VIIa in on-pump cardiac surgery.